Cholinergic muscarinic receptors are a family of G protein-coupled receptors (M₁–M₅) that are activated by the neurotransmitter acetylcholine and mediate parasympathetic nervous system responses in the central and peripheral nervous systems. These receptors regulate various physiological functions, including heart rate, smooth muscle contraction, glandular secretion, pupil constriction, and cognitive processes such as learning and memory.
Serotonin transporters (SERT) are specialized membrane proteins located on presynaptic serotonergic neurons that regulate serotonin neurotransmission by reabsorbing serotonin (5-hydroxytryptamine, 5-HT) from the synaptic cleft back into the nerve terminal after its release. This reuptake process terminates serotonin signaling and maintains neurotransmitter homeostasis in the central nervous system.
N-dehydroxylated metabolite is a metabolite formed when an N-hydroxyl group (-N–OH) is removed from a parent compound during metabolism, usually through enzymatic reduction. This biotransformation, primarily occurring in the liver, can alter the compound’s pharmacological activity, toxicity, and elimination. N-dehydroxylation is an important metabolic pathway for several drugs and xenobiotics, producing metabolites that may be less active, inactive, or, in some cases, possess different biological or toxicological properties compared with the parent compound.
Capillary permeability is the ability of capillary walls to allow the passage of water, ions, nutrients, proteins, and other molecules between the bloodstream and surrounding tissues. It is regulated by the structure of the endothelial cells and can increase during inflammation due to mediators such as histamine, bradykinin, and leukotrienes, allowing immune cells and plasma proteins to reach sites of injury or infection.
Leukotrienes are biologically active lipid mediators derived from arachidonic acid through the 5-lipoxygenase pathway, primarily produced by leukocytes such as mast cells, eosinophils, basophils, and macrophages. They play a central role in inflammation, allergic reactions, and immune responses by promoting bronchoconstriction, increasing vascular permeability, stimulating mucus secretion, and attracting inflammatory cells to sites of tissue injury.
Renal and hepatic impairment refers to the reduced functional capacity of the kidneys and liver, respectively, which can significantly alter the absorption, distribution, metabolism, and excretion of drugs. Renal impairment decreases the elimination of drugs and their metabolites, potentially leading to drug accumulation and toxicity, while hepatic impairment reduces drug metabolism, plasma protein synthesis, and biliary excretion, affecting drug clearance and increasing systemic exposure.
Bioavailability is a key pharmacokinetic parameter that describes the rate and extent to which an administered drug is absorbed and reaches the systemic circulation in an unchanged form, reflecting how much of the dose becomes available at the site of action, and it is influenced by factors such as drug formulation, route of administration, first-pass hepatic metabolism, solubility, and gastrointestinal absorption.
Bone marrow suppression is a condition in which the bone marrow’s ability to produce blood cells is reduced, leading to decreased levels of red blood cells, white blood cells, and platelets, and it may occur due to chemotherapy, radiation therapy, drugs, infections, or certain diseases.
DNA elongation is a crucial stage of DNA replication in which DNA polymerase enzymes synthesize new strands by continuously adding deoxyribonucleotides to the 3′ end of a growing DNA chain in the 5′→3′ direction, using the original DNA template strands as guides, while accessory proteins such as helicase, primase, and sliding clamps coordinate to ensure high fidelity, processivity, and accurate duplication of the genetic material before cell division.
Minimal hepatic metabolism refers to a pharmacokinetic property of a drug in which only a small proportion of the administered dose is metabolized by the liver, with most of the drug being eliminated unchanged through renal or other pathways.